Last reviewed · How we verify
Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines (COVID-19)
This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle (SARS-CoV-2 rS) vaccines with Matrix-M™ adjuvant (NVX-CoV2373 \[prototype Wuhan vaccine with Matrix-M adjuvant\] or NVX-CoV2601 \[Omicron XBB.1.5 subvariant vaccine with Matrix-M adjuvant\]).
Details
| Lead sponsor | Novavax |
|---|---|
| Phase | PHASE2, PHASE3 |
| Status | COMPLETED |
| Enrolment | 994 |
| Start date | Mon Oct 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue May 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- COVID-19
Interventions
- NVX-CoV2373 (5μg)
- NVX-CoV2601 (5μg)
- NVX-CoV2601(5μg)
- NVX-CoV2601 (35μg)
- NVX-CoV2601(35μg)
- NVX-CoV2601(50μg)
- Bivalent BA.4/5
Countries
United States